Vanja Podrascanin

Vanja Podrascanin

Auto-generated profile, based on publicly available information

Vanja Podrascanin

Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, USA; University Hospital Wiener Neustadt, Wiener Neustadt, Austria

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2025 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
MAMarkus Ammann
Markus Ammann
HGHallbera Gudmundsdottir
Hallbera Gudmundsdottir
SAStella K. Adjei Antwi
Stella K. Adjei Antwi
JSJonas Santol
Jonas Santol
VPVanja Podrascanin
Vanja Podrascanin
PSPatrick Starlinger
Patrick Starlinger

12 June 2026 in European Journal of Cancer
Verified
Journal Article
Closed access
YDYawen Dong
Yawen Dong
DPDavid Pereyra
David Pereyra
VPVanja Podrascanin
Vanja Podrascanin
ZLZhihao Li
Zhihao Li
JSJonas Santol
Jonas Santol
PSPatrick Starlinger
Patrick Starlinger

4 July 2025 in Liver Transplantation
Verified
Journal Article
Closed access
YDYawen Dong
Yawen Dong
LGLindsey A. Gregory
Lindsey A. Gregory
VPVanja Podrascanin
Vanja Podrascanin
JSJonas Santol
Jonas Santol
MAMarkus Ammann
Markus Ammann
PSPatrick Starlinger
Patrick Starlinger
Portal hypertension is a key factor in posthepatectomy liver failure (PHLF). While preoperative liver function tests like APRI+ALBI assess liver function, they only partially reflect portal hypertension severity. Elevated von Willebrand factor antigen (vWF-Ag) indicates endothelial dysregulation and correlates with portal hypertension. Combining vWF-Ag with APRI+ALBI may enhance PHLF prediction. A total of 534 patients who underwent liver resection at Mayo Clinic Rochester (2020–2024) were analyzed for PHLF incidence, postoperative morbidity, and 90-day mortality. Predictive probability for PHLF was assessed using receiver operating characteristic analysis and validated in an external Austrian cohort of 283 patients (2008–2017). vWF-Ag was then integrated into the existing APRI+ALBI multivariable model. PHLF grade B/C was reported in 56 patients (10.5%). The 90-day mortality rate was 0.9% (n=5). Using 2 cutoffs (182%, 240%), vWF-Ag was found to be an independent predictive factor for PHLF grade B/C that remained statistically significant upon multivariable analysis. The combination of preoperative APRI+ALBI and vWF-Ag increased the positive predictive value to 27.9% for PHLF grade B/C in the APRI+ALBI high and vWF-Ag high group. Incorporation of vWF-Ag into the established APRI+ALBI-based multivariable model revealed a superior AUC of 0.772 for PHLF risk stratification and was successfully validated in an independent cohort (AUC=0.834). The combination of vWF-Ag with APRI+ALBI demonstrates a favorable predictive potential for PHLF risk assessment. We provide 2 pathways for clinical assessment: (1) a cutoff-based system and (2) a more complex multivariable model that can be calculated in a specifically designed smartphone application.

21 June 2025 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
VPVanja Podrascanin
Vanja Podrascanin
MAMarkus Ammann
Markus Ammann
HGHallbera Gudmundsdottir
Hallbera Gudmundsdottir
YDYawen Dong
Yawen Dong
ZLZhihao Li
Zhihao Li
PSPatrick Starlinger
Patrick Starlinger

14 May 2026 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
YDYawen Dong
Yawen Dong
DPDavid Pereyra
David Pereyra
ZLZhihao Li
Zhihao Li
VPVanja Podrascanin
Vanja Podrascanin
JSJonas Santol
Jonas Santol
PSPatrick Starlinger
Patrick Starlinger

2 December 2025 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
VPVanja Podrascanin
Vanja Podrascanin
MAMarkus Ammann
Markus Ammann
HGHallbera Gudmundsdottir
Hallbera Gudmundsdottir
YDYawen Dong
Yawen Dong
JSJonas Santol
Jonas Santol
PSPatrick Starlinger
Patrick Starlinger